Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1899 1
1945 2
1946 1
1947 3
1952 1
1957 3
1960 1
1962 1
1964 2
1965 2
1966 1
1967 1
1968 1
1969 1
1970 2
1971 1
1972 2
1973 4
1977 2
1978 3
1979 1
1980 1
1983 1
1984 6
1985 2
1986 1
1988 1
1991 1
1992 5
1996 2
1997 3
2004 2
2006 1
2007 3
2008 4
2009 4
2010 4
2011 6
2012 2
2013 4
2014 7
2015 9
2016 10
2017 14
2018 12
2019 8
2020 8
2021 14
2022 15
2023 17
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Results by year

Filters applied: . Clear all
Page 1
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW. Hughes TP, et al. Among authors: ross dm. N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328. N Engl J Med. 2019. PMID: 31826340 Free PMC article. Clinical Trial.
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.
Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Döhner H, Falini B, Garcia-Manero G, Haferlach T, Hellström-Lindberg E, Kim AS, Klco JM, Komrokji R, Lee-Cheun Loh M, Loghavi S, Mullighan CG, Ogawa S, Orazi A, Papaemmanuil E, Reiter A, Ross DM, Savona M, Shimamura A, Skoda RC, Solé F, Stone RM, Tefferi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Duncavage EJ, et al. Among authors: ross dm. Blood. 2022 Nov 24;140(21):2228-2247. doi: 10.1182/blood.2022015853. Blood. 2022. PMID: 36130297 Free PMC article.
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross DM, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen NJ, Sellers WR. Wylie AA, et al. Among authors: ross dm. Nature. 2017 Mar 30;543(7647):733-737. doi: 10.1038/nature21702. Epub 2017 Mar 22. Nature. 2017. PMID: 28329763
Incidence of blast phase in myelofibrosis according to anemia severity.
Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, Palandri F, Iurlo A, De Stefano V, Kiladjian JJ, Elli EM, Polverelli N, Gotlib J, Albano F, Silver RT, Benevolo G, Ross DM, Devos T, Borsani O, Barbui T, Porta MGD, Bertù L, Komrokji R, Vannucchi AM, Passamonti F. Mora B, et al. Among authors: ross dm. EJHaem. 2023 Jul 17;4(3):679-689. doi: 10.1002/jha2.745. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601878 Free PMC article.
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Mesa RA, Hudgens S, Floden L, Harrison CN, Palmer J, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins A, Leahy MF, Deheshi S, Donahue R, Klencke BJ, Verstovsek S. Mesa RA, et al. Among authors: ross dm. Cancer Med. 2023 May;12(9):10612-10624. doi: 10.1002/cam4.5799. Epub 2023 Apr 6. Cancer Med. 2023. PMID: 37021939 Free PMC article. Clinical Trial.
Single cells tell multiple tales in CML.
Ross DM. Ross DM. Blood. 2023 Jun 1;141(22):2668-2670. doi: 10.1182/blood.2023020165. Blood. 2023. PMID: 37261852 No abstract available.
How much imatinib is enough?
Ross DM. Ross DM. Br J Haematol. 2021 May;193(4):699-700. doi: 10.1111/bjh.17444. Epub 2021 Apr 19. Br J Haematol. 2021. PMID: 33876424 No abstract available.
Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.
Lewis AC, Pope VS, Tea MN, Li M, Nwosu GO, Nguyen TM, Wallington-Beddoe CT, Moretti PAB, Anderson D, Creek DJ, Costabile M, Ali SR, Thompson-Peach CAL, Dredge BK, Bert AG, Goodall GJ, Ekert PG, Brown AL, D'Andrea R, Robinson N, Pitman MR, Thomas D, Ross DM, Gliddon BL, Powell JA, Pitson SM. Lewis AC, et al. Among authors: ross dm. Blood. 2022 Jun 30;139(26):3737-3751. doi: 10.1182/blood.2021013277. Blood. 2022. PMID: 35443029 Free PMC article.
Myeloid somatic mutation panel testing in myeloproliferative neoplasms.
Ross DM, Thomson C, Hamad N, Lane SW, Manos K, Grigg AP, Guo B, Erber WN, Scott A, Viiala N, Chee L, Latimer M, Tate C, Grove C, Perkins AC, Blombery P. Ross DM, et al. Pathology. 2021 Apr;53(3):339-348. doi: 10.1016/j.pathol.2021.01.003. Epub 2021 Mar 3. Pathology. 2021. PMID: 33674147 Review.
186 results